Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (26)
  • Aurora Kinase
    (11)
  • Autophagy
    (10)
  • FGFR
    (10)
  • FLT
    (89)
  • JAK
    (15)
  • PDGFR
    (20)
  • VEGFR
    (25)
  • c-Kit
    (25)
  • Others
    (109)
Filter
Search Result
Results for "

FLT3

" in TargetMol Product Catalog
  • Inhibitor Products
    221
    TargetMol | Activity
  • Recombinant Protein
    15
    TargetMol | inventory
  • PROTAC Products
    7
    TargetMol | natural
  • Natural Products
    3
    TargetMol | composition
  • Isotope products
    3
    TargetMol | Activity
FLT3-IN-3
T112982229050-90-0
FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.
  • $109
In Stock
Size
QTY
TargetMol | Citations Cited
FLT3/ITD-IN-3
T628242489446-47-9
FLT3/ITD-IN-3 (Compound 19) is a potent inhibitor of FLT3-ITD, acting on FLT3D835Y (IC50: 0.3 nM), FLT3 (IC50: 0.4 nM) and FLT3-ITD (IC50: 0.9 nM). FLT3/ITD-IN-3 showed potent inhibition of FLT3 phosphorylation and was effective against the proliferation of AML cells.
  • $1,520
6-8 weeks
Size
QTY
PDGFRα/FLT3-ITD-IN-3
T631272761259-22-5
PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be studied in acute myeloid leukaemia or chronic eosinophilic leukaemia. .
  • $1,520
6-8 weeks
Size
QTY
FLT3 kinase inhibitor 2HCl
T500722411178-94-2
3-amino-1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one dihydrochloride is used in the synthesis of various compounds.
  • $95
In Stock
Size
QTY
PROTAC FLT-3 degrader 1
T125552230826-81-8
PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FLT3-IN-23
T82392
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effects against BaF3 cells harboring diverse FLT3-TKD and FLT3-ITD-TKD mutations [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FLT3/CHK1-IN-1
T82393
Compound 18, also known as FLT3/CHK-IN-1, is a dual inhibitor targeting FLT3 and CHK1, exhibiting over 1700-fold selectivity towards c-KIT and significantly diminishing hERG affinity, with an IC50 of 58.4 μM. It demonstrates efficacy in suppressing tumor growth in mouse xenotransplantation models implanted with MV-4-11 cells [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FLT3-IN-10
T98562088735-51-5
FLT3-IN-10 (2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl-) (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).
  • $54
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FLT3-IN-15
T626072435562-99-3
FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).
  • $2,140
6-8 weeks
Size
QTY
FLT3-IN-2
T1938923562-23-6
FLT3-IN-2 is an FLT3 inhibitor (IC50<1 μM).
  • $36
In Stock
Size
QTY
FLT3/ITD-IN-1
T61415
FLT3/ITD-IN-1 (Compound 1) is a highly potent inhibitor of FLT3 internal tandem duplications (FLT3-ITD). It exhibits remarkable inhibitory effects against FLT3 and FLT3-ITD, with impressive IC50 values of 38.2 nM and 144.1 nM, respectively. Moreover, FLT3/ITD-IN-1 shows exceptional antiproliferative activities against several acute myeloid leukemia cell lines [1].
  • $1,520
10-14 weeks
Size
QTY
FLT3-IN-4
T112992304799-09-3
FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous leukemia.
  • $94
In Stock
Size
QTY
FLT3-IN-17
T631742758999-62-9
FLT3-IN-17 is an FAK inhibitor (IC50: 12 nM). FLT3-IN-17 inhibits the activity of CYPs and FLT3 mutants and has an IC50 of <0.5 nM for D835Y. FLT3-IN-17 can be used in cancer research.
  • $987
6-8 weeks
Size
QTY
FLT3-IN-14
T630582620551-45-1
FLT3-IN-14 is a potent inhibitor of FLT3, acting on FLT3-WT (IC50: 5.6 nM) and FLT3-ITD (IC50: 1.4 nM). FLT3-IN-14 inhibits FLT3 (Y591) phosphorylation, arrests the cell cycle in G1 phase and induces apoptosis.
  • $1,520
8-10 weeks
Size
QTY
FLT3-IN-12
T624122499966-67-3
FLT3-IN-12 is a selective, potent, orally active FLT3 kinase inhibitor that acts on FLT3-WT (IC50: 1.48 nM) and FLT3-D835Y (IC50: 2.87 nM). FLT3-IN-12 is more selective than c-KIT (>1000-fold). FLT3-IN-12 showed significant anti-AML effects, with an IC50 value of 0.75 nM for MV4-11 cells.
  • $1,520
6-8 weeks
Size
QTY
FLT3-IN-19
T781762237234-48-7
FLT3-IN-19 (Comp 50) is a potent, selective inhibitor of FLT3, demonstrating an IC50 value of 0.213 nM, and is applicable in research pertaining to acute myeloid leukemia (AML) [1].
  • Inquiry Price
Size
QTY
FLT3-IN-22
T79420
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant. This compound displays significant antiproliferative effects against MV4-11 cells and Ba/F3 cell lines expressing mutant FLT kinase variants, such as FLT-D835Y and FLT3-F691L [1].
  • Inquiry Price
Size
QTY
FLT3-IN-18
T73142752191-77-8
FLT3-IN-18, a potent and selective FLT3 inhibitor, exhibits an IC50 value of 0.003 μM. It effectively induces apoptosis and G1 phase cell cycle arrest, while inhibiting FLT3 and STAT5 phosphorylation. This compound holds potential for acute myeloid leukemia (AML) research.
  • $1,520
6-8 weeks
Size
QTY
PROTAC FLT3/CDK9 degrader-1
T74707
PROTAC FLT3/CDK9 degrader-1, a potent dual degrader of FLT3 and CDK9, effectively induces apoptosis and targets protein degradation of FLT3 and CDK9. This compound holds research potential for FLT3-ITD mutated AML [1].
  • Inquiry Price
Size
QTY
FLT3-IN-16
T9843298207-49-5
FLT3-IN-16 exhibits potent inhibitory activity against FLT3 tyrosine kinase with an IC 50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia [1].
  • $51
In Stock
Size
QTY
FLT3-IN-13
T61101
FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1].
  • $1,520
10-14 weeks
Size
QTY
JAK2/FLT3-IN-1 TFA
T64104
JAK2/FLT3-IN-1 (TFA) is an orally active dual inhibitor of JAK2/FLT3 that exhibits anticancer effects, acting on JAK2 (IC50: 0.7 nM), FLT3 (IC50: 4 nM), JAK1 (IC50: 26 nM) and JAK3 (IC50: 39 nM).
  • $2,120
10-14 weeks
Size
QTY
FLT3/TrKA-IN-1
T62801
FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor, capable of acting on FLT3 (IC50: 43.8 nM), FLT3-ITD (IC50: 97.2 nM), FLT3-TKD (IC50: 92.5 nM) and TrKA (IC50: 23.6 nM). -FLT3/TrKA-IN-1 has potential for acute myeloid leukaemia (AML) studies.
  • $1,520
10-14 weeks
Size
QTY
FLT3/ITD-IN-4
T628632278278-04-7
FLT3/ITD-IN-4 (Compound 16) is a selective inhibitor of FLT3 internal tandem repeat mutations (FLT3-ITD) (IC50: 2.3 nM). FLT3/ITD-IN-4 can be used to study acute myeloid leukaemia.
  • $1,520
8-10 weeks
Size
QTY
FLT3-IN-11
T622602499966-50-4
FLT3-IN-11 (compound 30) is an orally active, potent and selective inhibitor of FLT3 kinase, acting on wild-type FLT3 (IC50: 7.22 nM) and FLT3-D835Y (IC50: 4.95 nM). FLT3-IN-11 exhibited significant anti-AML effects with an IC50 value of 3.2 nM for MV4-11 cells.
  • $1,520
6-8 weeks
Size
QTY
FLT3/D835Y-IN-1
T619772648799-49-7
FLT3/D835Y-IN-1 (compound 13a) is a orally active, and selective inhibitor of FLT3 and FLT3/D835Y, with IC50s of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 has anticancer efficacy, and has research value in AML (acute myeloid leukemia).
  • $1,520
6-8 weeks
Size
QTY
FLT3-IN-6
T113002377141-31-4
FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.
  • $332
6-8 weeks
Size
QTY
FLT3/ITD-IN-2
T632742489446-59-3
FLT3/ITD-IN-2 is a potent inhibitor of FLT3-ITD and is able to act on FLT3D835Y (IC50: 0.3 nM), FLT3 (IC50: 0.4 nM) and FLT3-ITD (IC50: 1.0 nM).FLT3/ITD-IN-2 effectively inhibits the phosphorylation of FLT3 and is able to effectively inhibit the proliferation of acute myeloid leukemia cells.
  • $1,520
6-8 weeks
Size
QTY
FLT3-IN-21
T79391
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase. It effectively inhibits the proliferation of FLT3-ITD-positive AML cells MV-4-11, with an IC50 of 5.3 nM. In murine models, a daily dose of 10 mg/kg FLT3-IN-21 markedly inhibited tumor growth in the MV-4-11 xenograft model, achieving a tumor growth inhibition (TGI) of 92.16% [1].
  • Inquiry Price
Size
QTY
FLT3-IN-20
T79596
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD. It exhibits anti-proliferative effects on FLT3-ITD-positive AML cell lines, with IC50s of 7 nM in MV4-11 and 9 nM in MOLM-13, as well as 4 nM in a MOLM-13 variant harboring the FLT3-ITD-D835Y mutation. FLT3-IN-20 is utilized in cancer research [1].
  • Inquiry Price
Size
QTY
MDK5466
T24438852045-46-6
MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.
  • $1,520
6-8 weeks
Size
QTY
PDGFRα/FLT3-ITD-IN-2
T636292761259-09-8
PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM). PDGFRα/FLT3-ITD-IN-2 has shown investigational potential in acute myeloid leukemia or chronic eosinophilic leukemia.
  • $1,520
6-8 weeks
Size
QTY
TCS 359
T6138301305-73-7
TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.
  • $31
In Stock
Size
QTY
PDGFRα/FLT3-ITD-IN-1
T634542761259-05-4
PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 exhibits investigational potential in acute myeloid leukemia or chronic eosinophilic leukemia.
  • $1,520
6-8 weeks
Size
QTY
Flt3 Inhibitor IV
T24067819058-89-4
Flt3 Inhibitor IV is a potent ATP-competitive Flt3 inhibitor.
  • $1,520
6-8 weeks
Size
QTY
FLT3/CDK4-IN-1
T631352762296-44-4
FLT3/CDK4-IN-1 is a highly selective, potent, orally active dual inhibitor of FLT3/CDK4, acting on FLT3 (IC50: 7 nM) and CDK4 (IC50: 11 nM).FLT3/CDK4-IN-1 has good anti-tumour effects in vivo, showing anti-proliferative effects on some cancer cells.
  • $1,520
6-8 weeks
Size
QTY
SKLB4771
T20511370256-78-2
SKLB4771 (FLT3-IN-1) is a novel potent and selective Flt3 inhibitor.
  • $61
In Stock
Size
QTY
JAK2/FLT3-IN-1
T117072387765-27-5
JAK2/FLT3-IN-1 has anti-cancer activity. JAK2/FLT3-IN-1 is a potent and orally effective dual JAK2/FLT3 (Janus kinase 2/ FMS-like tyrosine kinase 3) inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively.
  • $1,520
6-8 weeks
Size
QTY
c-Met/MEK1/Flt-3-IN-1
T72407
Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-dependent manner by arresting A549 cells in the G1 phase.
  • $1,970
8-10 weeks
Size
QTY
Edicotinib
T151991142363-52-7
Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effects on KIT and FLT3 (IC50: 20 nM and 190 nM). It has the potential for Alzheimer's disease and rheumatoid arthritis treatment.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Pexidartinib
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Sorafenib
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity and can induce autophagy and apoptosis as well as agonistic ferroptosis.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Fedratinib
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
  • $45
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Quizartinib
T2066950769-58-1
Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Cabozantinib
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Gilteritinib
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preClinicalal studies, gilteritinib showed strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 Clinicalal trials for acute myeloid leukemia.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
BPR1J-097 hydrochloride (1327167-19-0(free base))
T4261
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
  • $43
In Stock
Size
QTY
JI6
T64370856436-16-3In house
JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits c-Kit and JAK3, with IC50s of ∼500 and ∼250 nM, respectively. JI6 has research value in acute myeloid leukemia.
  • $163
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AZ7550 hydrochloride
T13564L2309762-40-9
AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
  • $126
In Stock
Size
QTY
Cabozantinib hydrochloride
T51641817759-42-4
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
  • $37
In Stock
Size
QTY